Compare CTS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTS | ANAB |
|---|---|---|
| Founded | 1896 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1994 | 2015 |
| Metric | CTS | ANAB |
|---|---|---|
| Price | $52.37 | $54.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $62.20 |
| AVG Volume (30 Days) | 180.3K | ★ 408.5K |
| Earning Date | 05-13-2026 | 04-06-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | ★ 15.87 | 15.79 |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $541,318,000.00 | $91,280,000.00 |
| Revenue This Year | $5.55 | $135.51 |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $24.37 | ★ N/A |
| Revenue Growth | 4.95 | ★ 432.03 |
| 52 Week Low | $34.02 | $14.01 |
| 52 Week High | $59.66 | $57.74 |
| Indicator | CTS | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.59 | 57.44 |
| Support Level | $40.41 | $43.67 |
| Resistance Level | $59.66 | $57.65 |
| Average True Range (ATR) | 1.76 | 3.50 |
| MACD | -0.67 | 0.03 |
| Stochastic Oscillator | 9.27 | 68.78 |
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).